Search Results

Florida Cancer Specialists & Research Institute, LLC (FCS) physicians will present findings from multiple clinical studies that are contributing to global advancements in cancer care at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting in Chicago.

Inocras and IMBdx have announced a partnership aimed at enhancing care for cancer patients in the U.S.

Florida Cancer Specialists & Research Institute, LLC is proud to announce an initiative aimed at revolutionizing cancer care – the introduction of designated FCS Disease Site Teams for late-phase research and the subsequent formation of the FCS Disease Site Committee.

Leal Health (“Leal’’ or “the Company’’), a patient-first, AI-powered treatment platform revolutionizing patient access to cancer care, announced today that it will unveil new data on the benefits of digital health and AI-powered platforms for bridging cancer care gaps among diverse patient populations at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting.

Photocure ASA, the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the 2024 European Association of Urology congress in Paris, France, highlighting the benefits of Blue Light Cystoscopy in Bladder Cancer management.

Accuray Incorporated announced that long-term customer Heidelberg University Hospital in Heidelberg, Germany, has selected the company’s Radixact® System, equipped with its proprietary ClearRT®, Synchrony® and VOLO™ Ultra Optimizer solutions, to help transform their approach to cancer care.

DiaCarta, Inc. (“DiaCarta”), a pioneer in developing innovative molecular technologies to transform patient care by providing effective precision diagnostics using liquid biopsy in cancer and infectious diseases has established a strategic collaboration with Capstone Health Alliance, one of the largest regional group purchasing organizations (GPO) in the US healthcare sector.

The National Comprehensive Cancer Network® is announcing 2024 award recipients that include individuals and groups who have made significant and noteworthy impacts on improving cancer care and supporting NCCN’s mission to help all people with cancer to live better lives.

Inocras and Massive Bio, a cutting-edge AI-driven clinical trial matching platform provider, have joined forces to set a new standard for cancer patient care.